{
    "2019-05-06": [
        [
            {
                "time": "2019-04-30",
                "original_text": "Daily Dividend Report: LLY, CSX, KLAC, TFX, R",
                "features": {
                    "keywords": [
                        "Dividend",
                        "LLY",
                        "CSX",
                        "KLAC",
                        "TFX"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "industrials",
                        "technology",
                        "financials"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-30",
                "original_text": "Lilly Declares Second-Quarter 2019 Dividend",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Dividend",
                        "Second-Quarter",
                        "2019"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-30",
                "original_text": "AAN 2019: Pooled Analyses of Two EmgalityÂ® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups",
                "features": {
                    "keywords": [
                        "AAN",
                        "Emgality",
                        "Phase 3",
                        "Migraine",
                        "Headache",
                        "Reduction"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-30",
                "original_text": "Edited Transcript of LLY earnings conference call or presentation 30-Apr-19 1:00pm GMT",
                "features": {
                    "keywords": [
                        "LLY",
                        "earnings",
                        "conference",
                        "call",
                        "presentation"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}